Organisation paid for research Program year 2021 Source: CMS Open Payments

Columbus Regional Research

Neither a doctor nor a teaching hospital

Research payments

$98,137

48 payments

Through program year 2021, Columbus Regional Research is reported as receiving $98,137 in research payments, across 48 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $7,318 9
2020 Research $7,730 11
2019 Research $83,089 28

Breakdown

Who paid Research payments · program years 2019–2021
  1. Ironwood Pharmaceuticals, Inc $31,463 2 payments
  2. TESARO, Inc. $26,762 1 payment
  3. Shire North American Group Inc $24,864 25 payments
  4. Array BioPharma Inc. $9,817 13 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $5,231 7 payments
Studies the money was for Research payments · program years 2019–2021
  1. C3718-302 $31,463 2 payments
  2. Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With Pembrolizumab in Patients With Non-Small Cell Lung Cancer $26,762 1 payment
  3. A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis Aida $12,235 6 payments
  4. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 301 $9,858 10 payments
  5. A Phase 3 Multinational Randomized Placebocontrolled Study of Arry371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due to A Lamin Ac Gene Mutation $7,730 11 payments
  6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 301) $5,231 7 payments
  7. Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $2,771 9 payments
  8. A Phase 3 Multinational Randomized Placebocontrolled Study of Arry371797 Pf07265803 in Patients With Symptomatic Dilated Cardiomyopathy Due to A Lamin Ac Gene Mutation $2,087 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record